Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically/cytologically confirmed stage IIIB (pleural or pericardial effusion) or stage IV NSCLC~* Age \> 18 years~* ECOG PS \< 2~* No prior chemotherapy~* Measurable disease~* Signed informed consent~* Adequate bone marrow function~* Adequate renal function~* Adequate hepatic function~Exclusion Criteria:~* Untreated clinically active brain metastasis~* Radiotherapy within 2 weeks prior to initiation of protocol therapy~* Treatment with any investigational therapy within 4 weeks prior to enrollment~* History of any cancer other than NSCLC (except non-melanoma skin cancer or carcinoma on situ of the cervix) within the last 5 years~* Patients in their reproductive age group should use an effective method of birth control. Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter. Patients who are breast-feeding will be excluded from the study. Women of childbearing potential must have a negative pregnancy test.~* Major surgery within 3 weeks prior to enrollment~* Use of immunosuppressive agents including systemic corticosteroids within 4 weeks prior to enrollment (corticosteroids are permitted as physiological replacement therapy or as supportive care for nausea and emesis)~* Known history of Human immunodeficiency virus infection~* Any co-morbidity or condition of sufficient severity to limit full compliance with the protocol per assessment by the investigator~* Concurrent serious medical infection or illness, or psychiatric illness likely to interfere with participation in this clinical study.~* History of known hypersensitivity to docetaxel or other drugs formulated with polysorbate 80, bortezomib, boron or mannitol~* Patient has Grade 2 peripheral neuropathy within 14 days before enrollment.~* Myocardial infarction within 6 months prior to enrollment or has New York Hospital Association (NYHA) Class III or IV heart failure (see section 8.4), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Phase I - Dose Level 1 (Type: EXPERIMENTAL): Carboplatin AUC 5 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
- Phase I - Dose Level 2A (Type: EXPERIMENTAL): Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
- Phase I - Dose Level 2B (Type: EXPERIMENTAL): Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
- Phase I - Dose Level 3 (Type: EXPERIMENTAL): Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
- Phase I - Dose Level 4 (Type: EXPERIMENTAL): Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 75 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
- Phase I - Dose Level 5 (Type: EXPERIMENTAL): Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 75 mg/m2 (Day 1) Bortezomib 1.3 mg/m2 (Day 1,4,8,11)
- Phase II (Type: EXPERIMENTAL): Carboplatin AUC 5 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues